• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4612197)   Today's Articles (4506)   Subscriber (49382)
For: Chen C, Li N, Shentu Y, Pang L, Beckman RA. Adaptive Informational Design of Confirmatory Phase III Trials With an Uncertain Biomarker Effect to Improve the Probability of Success. Stat Biopharm Res 2016. [DOI: 10.1080/19466315.2016.1173582] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Number Cited by Other Article(s)
1
Xu H, Liu Y, Beckman RA. Adaptive Endpoints Selection with Application in Rare Disease. Stat Biopharm Res 2023. [DOI: 10.1080/19466315.2023.2183252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
2
Chen DQ, Mao SQ, Niu XF. Tests and classification methods in adaptive designs with applications. J Appl Stat 2022;50:1334-1357. [PMID: 37025279 PMCID: PMC10071978 DOI: 10.1080/02664763.2022.2026898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
3
Lu Y, Zhou J, Xing L, Zhang X. The optimal design of clinical trials with potential biomarker effects: A novel computational approach. Stat Med 2021;40:1752-1766. [PMID: 33426649 DOI: 10.1002/sim.8868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 11/03/2020] [Accepted: 12/16/2020] [Indexed: 11/06/2022]
4
Li AJ, Dhanraj JP, Lopes G, Parker JL. Clinical trial risk in leukemia: Biomarkers and trial design. Hematol Oncol 2020;39:105-113. [PMID: 33078436 DOI: 10.1002/hon.2818] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 09/28/2020] [Accepted: 10/06/2020] [Indexed: 12/12/2022]
5
Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A, Yamamoto N, Nakamura K, Nishida T, Fujiwara Y. MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial. Clin Pharmacol Ther 2020;108:596-605. [PMID: 32112563 PMCID: PMC7484913 DOI: 10.1002/cpt.1817] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 01/22/2020] [Indexed: 12/28/2022]
6
Ghadessi M, Tang R, Zhou J, Liu R, Wang C, Toyoizumi K, Mei C, Zhang L, Deng CQ, Beckman RA. A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet J Rare Dis 2020;15:69. [PMID: 32164754 PMCID: PMC7069184 DOI: 10.1186/s13023-020-1332-x] [Citation(s) in RCA: 71] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 02/07/2020] [Indexed: 11/26/2022]  Open
7
De Martini D. Empowering phase II clinical trials to reduce phase III failures. Pharm Stat 2019;19:178-186. [PMID: 31729173 DOI: 10.1002/pst.1980] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 07/03/2019] [Accepted: 07/15/2019] [Indexed: 12/13/2022]
8
Chen C, Li X(N, Li W, Beckman RA. Adaptive expansion of biomarker populations in phase 3 clinical trials. Contemp Clin Trials 2018;71:181-185. [DOI: 10.1016/j.cct.2018.07.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2017] [Revised: 04/03/2018] [Accepted: 07/04/2018] [Indexed: 10/28/2022]
9
Auto-adaptive Alpha Allocation: A Strategy to Mitigate Risk on Study Assumptions. STATISTICS IN BIOSCIENCES 2018. [DOI: 10.1007/s12561-017-9192-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
10
Zhang W, Wang J, Menon S. Advancing cancer drug development through precision medicine and innovative designs. J Biopharm Stat 2017;28:229-244. [PMID: 29173004 DOI: 10.1080/10543406.2017.1402784] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
11
Cunanan KM, Iasonos A, Shen R, Hyman DM, Riely GJ, Gönen M, Begg CB. Specifying the True- and False-Positive Rates in Basket Trials. JCO Precis Oncol 2017;1:1700181. [PMID: 32913969 DOI: 10.1200/po.17.00181] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]  Open
12
Benner L, Kieser M. Timing of the interim analysis in adaptive enrichment designs. J Biopharm Stat 2017;28:622-632. [PMID: 29064745 DOI: 10.1080/10543406.2017.1372769] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
13
Li W, Chen C, Li X, Beckman RA. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines. Stat Med 2017;36:1843-1861. [PMID: 28303586 DOI: 10.1002/sim.7272] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 02/14/2017] [Indexed: 12/26/2022]
14
Adaptive Biomarker Population Selection in Phase III Confirmatory Trials with Time-to-Event Endpoints. STATISTICS IN BIOSCIENCES 2016. [DOI: 10.1007/s12561-016-9178-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA